Scientific Advisory Council

Michael Kalos, PhD

Next Pillar Consulting, LLC

Philadelphia, PA

Dr. Michael Kalos is a recognized international key opinion leader in the fields of immunotherapy and biomarkers.

Previously, Dr. Kalos was Executive Vice President and Head of Research and Development at ArsenalBio. He also served as Vice President, Immunooncology and Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies of Johnson and Johnson, and chief scientific officer at Eli Lilly & Company. He fleshed out their immuno-oncology strategy, integrated their programs, and made them more comprehensive. He has also led efforts to improve the way that doctors evaluate early stage immunotherapy protocols, and has also been involved in developing promising immunotherapies such as CAR T cells. 

In addition to being a member of CRI’s Scientific Advisory Council, Dr. Kalos serves on the Cancer Immunotherapy Consortium (CIC) Steering Committee.

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.